Sugi Predict

Sugi Predict / Compounds / SCHEMBL25338181

SCHEMBL25338181

SCHEMBL25338181

CC(N)C1CCC(n2cc(NC(=O)OC(C)(C)C)c(C(F)F)n2)CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 3/20 0.34
▸ ROCK2 O75116 5/20 0.34
▸ ROCK1 Q13464 5/20 0.34
▸ PKN2 Q16513 4/20 0.34
▸ RPS6KA5 O75582 3/20 0.34
▸ LRRK2 Q5S007 3/20 0.34
▸ TP53 P04637 2/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ PRKD3 O94806 2/20 0.34
▸ CDK1 P06493 2/20 0.34
▸ CDK2 P24941 2/20 0.34
▸ LTK P29376 2/20 0.34
▸ CDK8 P49336 2/20 0.34
▸ PRKX P51817 2/20 0.34
▸ PRKCQ Q04759 2/20 0.34
▸ PRKCD Q05655 2/20 0.34
▸ STK3 Q13188 2/20 0.34
▸ CDC42BPA Q5VT25 2/20 0.34
▸ BRSK1 Q8TDC3 2/20 0.34
▸ CLK4 Q9HAZ1 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25969140 1.00 AAK1 (0.34) AAK1ROCK2ROCK1PKN2RPS6KA5
SCHEMBL25969171 1.00 AAK1 (0.34) AAK1ROCK2ROCK1PKN2RPS6KA5
SCHEMBL25969167 0.92 GFER (0.33) AAK1IRAK4PIK3CDABL1EGFR
SCHEMBL25339977 0.92 GFER (0.33) AAK1IRAK4PIK3CDABL1EGFR
SCHEMBL23744953 0.87 OPRM1 (0.39) IRAK4RORC
SCHEMBL25339817 0.86 GFER (0.33) IRAK4GFERRORC
SCHEMBL25969170 0.86 GFER (0.33) IRAK4GFERRORC
SCHEMBL21997531 0.85 IRAK4 (0.39) AAK1LRRK2IRAK4GFERRORC
SCHEMBL21996690 0.85 GFER (0.33) IRAK4GFERRORC
SCHEMBL23744955 0.85 IRAK4 (0.39) AAK1LRRK2IRAK4GFERRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-09 — — US disclosed
EP-4472967-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-12-11 — — EP disclosed
CN-118973581-A IRAK degradation agent and application thereof 凯麦拉医疗公司 2024-11-15 — — CN disclosed
US-12091411-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-17 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
WO-2023147594-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 AAK1 1009/4885ROCK2 2938/4885ROCK1 2753/4885
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 AAK1 1009/4885ROCK2 2938/4885ROCK1 2753/4885
US-12091411-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 AAK1 1009/4885ROCK2 2938/4885ROCK1 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.